Women's HRT & Perimenopause

What is perimenopause?

Perimenopause is the transition leading up to menopause. Ovarian hormone production becomes less predictable, and ovulation occurs less consistently. Symptoms can appear while you are still menstruating.

Menopause is generally confirmed after 12 consecutive months without a period, when there is no other explanation and you are not using a treatment that changes bleeding patterns. The years afterward are called postmenopause. ^{[1, 2]}

You do not need to wait until your periods stop to discuss bothersome symptoms or treatment. ^[3]

Perimenopause symptoms: more than hot flashes

Symptoms vary. Some women notice a few changes; others find the transition affects sleep, work, exercise, and relationships.

These symptoms are recognized around the menopause transition, but they do not prove that hormones are the cause. Thyroid disorders, anemia, sleep problems, medications, and other conditions can overlap. A clinical evaluation helps clarify what needs attention. ^{[1, 2]}

Track what has changed

Bring notes about your periods, sleep, hot flashes, mood, and any vaginal or urinary symptoms. Include when changes began and how they affect daily life. A pattern over time is often more useful than trying to remember everything during an appointment. ^{[1, 4]}

Can my labs look normal and still be perimenopause?

Yes. Hormone levels fluctuate during the transition, so one result may not capture the pattern.

For otherwise healthy women age 45 or older with typical symptoms and menstrual changes, guidelines generally identify perimenopause clinically rather than requiring hormone tests. Testing may be appropriate at younger ages, when the picture is unclear, or to investigate another condition. ^[4]

This differs from diagnosing male testosterone deficiency. Women's HRT decisions should not depend on a universal “optimal” estrogen, progesterone, or testosterone number.

If symptoms begin before age 45—especially before 40—seek evaluation for early menopause or premature ovarian insufficiency. ^{[4, 5]}

What is women's HRT?

Hormone replacement therapy, also called menopausal hormone therapy, uses prescription hormones to treat menopause-related symptoms. Estrogen is the main treatment for hot flashes and night sweats. A progestogen, such as progesterone, is usually added when a woman has a uterus to protect its lining. ^[3]

Treatment depends on symptoms, menstrual stage, medical history, and preferences.

Estrogen, progesterone, and local treatment

Low-dose vaginal estrogen is different from systemic therapy: it generally produces much less bloodstream exposure and does not treat hot flashes. A progestogen is generally not required with low-dose vaginal estrogen alone. ^{[3, 4]}

Women without a uterus can often use estrogen alone, although individual circumstances may change the plan. ^[3]

What can HRT help with?

Systemic hormone therapy is the most effective treatment for bothersome hot flashes and night sweats. It can also help prevent bone loss. Vaginal treatment can relieve dryness and discomfort. ^[3]

Sleep and some mood symptoms may improve, particularly when disruptive menopause symptoms are contributing. HRT does not replace evaluation or treatment for depression, anxiety disorders, or other causes of insomnia. ^{[4, 5]}

HRT is not a guaranteed weight-loss, hair-restoration, or memory treatment. The goal is meaningful symptom relief with an appropriate treatment plan.

What about testosterone for women?

Testosterone has a narrower evidence base than estrogen for menopause symptoms. Its best-supported use is for appropriately assessed hypoactive sexual desire disorder (HSDD), especially after menopause: persistently low sexual desire that causes personal distress.

What testosterone can do for women

For the right patient, the benefits can be meaningful. An international consensus of medical societies reviewed the research on postmenopausal women with low desire that causes distress. It found that carefully dosed testosterone can improve: ^[12]

• Sexual desire: more interest in intimacy
• Arousal and responsiveness
• Orgasm
• Sexual satisfaction: on average, about one more satisfying sexual experience a month than placebo

Desire is closely tied to feeling close, confident, and connected. When low desire has become part of the gap between partners, treating it appropriately can matter to both of you.

How it's prescribed well

• Transdermal (through the skin), at doses that keep levels within the normal range for premenopausal women
• A baseline testosterone level before starting, a recheck about 3–6 weeks in, then monitoring about every 6 months
• A clear review point: if there's no benefit after about 6 months, treatment should be stopped ^[12]

Low desire needs a full assessment, including pain, medications, mental health, relationship factors, and other contributors. A low testosterone blood level alone does not diagnose HSDD.

In the United States, testosterone treatment for women is off-label; there is no FDA-approved testosterone product specifically for women. Guidelines favor carefully dosed transdermal treatment and monitoring to keep levels within the physiologic premenopausal range. Evidence in premenopausal women is more limited.

Testosterone is not an established treatment for general fatigue, brain fog, muscle gain, or weight loss. Potential adverse effects include acne and increased hair growth; excessive exposure can cause more serious androgen effects. Long-term safety remains uncertain. ^[6]

What does “bioidentical” mean?

Bioidentical describes hormones with the same molecular structure as those made by the body. FDA-approved estradiol and micronized progesterone products are available.

Bioidentical does not automatically mean compounded or risk-free. Compounded products are not FDA-approved and have not been shown to be safer or more effective than approved options. ACOG recommends FDA-approved menopausal hormone therapy when an appropriate approved product is available. ^[7]

Benefits, risks, and choosing the right approach

For many healthy symptomatic women younger than 60 or within 10 years of menopause onset, the benefit-risk balance of systemic hormone therapy is favorable. Individual assessment still matters. ^[3]

Risks depend on age, medical history, route, formulation, and duration. Oral estrogen carries greater blood-clot risk than transdermal estrogen. Combined estrogen-progestogen therapy can increase breast cancer risk with longer use. Systemic estrogen without appropriate uterine protection increases endometrial cancer risk. ^[3]

Discuss a history of hormone-sensitive cancer, blood clots, stroke, heart disease, liver disease, unexplained vaginal bleeding, or possible pregnancy before treatment. Systemic HRT may be unsuitable, or specialist assessment may be needed. ^{[5, 8]}

Have the FDA warnings changed?

In February 2026, the FDA approved labeling changes for an initial six menopausal hormone therapy products, removing cardiovascular disease, breast cancer, and probable dementia risk statements from their boxed warnings.

That change does not mean every product is risk-free. Read the current product-specific information and discuss your own benefits and risks with the prescriber. ^[9]

Follow-up and symptom monitoring

Treatment should be reassessed after starting or changing a regimen. A review around three months is common, followed by at least annual reassessment when stable.

Follow-up considers symptom relief, side effects, bleeding, blood pressure, and changes in health. Routine hormone panels are not necessary for everyone; tests should serve a clinical purpose. ^{[4, 5]}

Women's HRT FAQs